{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T19:21:30Z","timestamp":1793647290415,"version":"4.5.1"},"reference-count":156,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Toxicol"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s12012-026-10104-z","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T12:47:22Z","timestamp":1771937242000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Beyond Remission: The Cardiotoxic and Thrombotic Shadow of AML Chemotherapy"],"prefix":"10.1007","volume":"26","author":[{"given":"Farshad","family":"Heydari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Feli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohsen","family":"Maleknia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeinab","family":"Habibi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armin","family":"Sohrabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Hamblin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jalal","family":"Naghinezhad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,24]]},"reference":[{"issue":"1","key":"10104_CR1","first-page":"46","volume":"75","author":"HM Kantarjian","year":"2025","unstructured":"Kantarjian, H. M., DiNardo, C. D., Kadia, T. M., Daver, N. G., Altman, J. K., Stein, E. M., et al. (2025). Acute myeloid leukemia management and research in 2025. CA Cancer Journal for Clinicians, 75(1), 46\u201367.","journal-title":"CA Cancer Journal for Clinicians"},{"issue":"5","key":"10104_CR2","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1002\/ajh.27625","volume":"100","author":"S Shimony","year":"2025","unstructured":"Shimony, S., Stahl, M., & Stone, R. M. (2025). Acute myeloid leukemia: 2025 Update on diagnosis, risk-stratification, and management. American Journal of Hematology, 100(5), 860\u201391.","journal-title":"American Journal of Hematology"},{"issue":"8","key":"10104_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.110458","volume":"27","author":"Y Lei","year":"2024","unstructured":"Lei, Y., Wei, H., & Gao, X. (2024). High temporal resolution prediction of mortality risk for single AML patient via deep learning. iScience, 27(8), Article 110458.","journal-title":"iScience"},{"issue":"2","key":"10104_CR4","doi-asserted-by":"publisher","DOI":"10.1111\/jrh.70028","volume":"41","author":"J Sheng","year":"2025","unstructured":"Sheng, J., Heiney, S. P., Wickersham, K. E., Nguyen, L. A., Harrison, K. W., & Adams, S. A. (2025). Living with chronic myelogenous leukemia in rural communities: Exploring factors related to tyrosine kinase inhibitors adherence with a mixed methods approach. Journal of Rural Health, 41(2), Article e70028.","journal-title":"Journal of Rural Health"},{"key":"10104_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2024.107505","volume":"141","author":"A Mohebbi","year":"2024","unstructured":"Mohebbi, A., Shahriyary, F., Farrokhi, V., Bandar, B., & Saki, N. (2024). A systematic review of second-generation FLT3 inhibitors for treatment of patients with relapsed\/refractory acute myeloid leukemia. Leukemia Research, 141, Article 107505.","journal-title":"Leukemia Research"},{"issue":"5","key":"10104_CR6","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.31557\/APJCP.2021.22.5.1407","volume":"22","author":"SM Samosir","year":"2021","unstructured":"Samosir, S. M., Utamayasa, I. K. A., Andarsini, M. R., Rahman, M. A., Ontoseno, T., Hidayat, T., et al. (2021). Risk factors of Daunorubicine induced early cardiotoxicity in childhood acute lymphoblastic leukemia: A retrospective study. Asian Pacific Journal of Cancer Prevention, 22(5), 1407\u20131412.","journal-title":"Asian Pacific Journal of Cancer Prevention"},{"issue":"5","key":"10104_CR7","first-page":"655","volume":"6","author":"M Camilli","year":"2024","unstructured":"Camilli, M., Cipolla, C. M., Dent, S., Minotti, G., & Cardinale, D. M. (2024). Anthracycline cardiotoxicity in adult cancer patients: JACC: CardioOncology state-of-the-art review. JACC: CardioOncology, 6(5), 655\u201377.","journal-title":"JACC: CardioOncology"},{"issue":"8","key":"10104_CR8","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.3390\/cancers15082267","volume":"15","author":"B Boluda","year":"2023","unstructured":"Boluda, B., Solana-Altabella, A., Cano, I., Mart\u00ednez-Cuadr\u00f3n, D., Acu\u00f1a-Cruz, E., Torres-Mi\u00f1ana, L., Rodr\u00edguez-Veiga, R., Navarro-Vicente, I., Mart\u00ednez-Campuzano, D., Garc\u00eda-Ruiz, R., & Lloret, P. (2023). Incidence and risk factors for development of cardiac toxicity in adult patients with newly diagnosed acute myeloid leukemia. Cancers, 15(8), 2267.","journal-title":"Cancers"},{"key":"10104_CR9","doi-asserted-by":"crossref","unstructured":"Geels, J. R. A., Gradowska, P., Asselbergs, F. W., & Linschoten, M. (2025). Heart failure in patients with acute myeloid leukemia (AML) treated with anthracycline agents during remission induction therapy: A systematic review and meta-analysis. ACUTE MYELOID LEUKEMIA. Leukemia.","DOI":"10.1038\/s41375-025-02753-w"},{"key":"10104_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17030541","author":"KC Siaravas","year":"2025","unstructured":"Siaravas, K. C., Moula, A. I., Tzourtzos, I. S., Ballas, C. E., & Katsouras, C. S. (2025). Acute and chronic cardiovascular adverse events in patients with acute myeloid leukemia: A systematic review. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers17030541","journal-title":"Cancers (Basel)"},{"key":"10104_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15113060","author":"M Mitrovic","year":"2023","unstructured":"Mitrovic, M., Pantic, N., Sabljic, N., Bukumiric, Z., Virijevic, M., Pravdic, Z., et al. (2023). Arterial thrombosis in patients with acute myeloid leukemia: Incidence and risk factors. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers15113060","journal-title":"Cancers (Basel)"},{"key":"10104_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2024.107456","author":"GGO Sanchez-Petitto","year":"2024","unstructured":"Sanchez-Petitto, G. G. O., Masur, J., Childress, J., Iqbal, T., An, M., Muhammad, S., Lawson, J., Li, G., Barr, B., & Emadi, A. (2024). Clinical outcomes of patients with acute myeloid leukemia and cardiovascular disease. Leukemia Research. https:\/\/doi.org\/10.1016\/j.leukres.2024.107456","journal-title":"Leukemia Research"},{"key":"10104_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2023.116791","volume":"482","author":"M Chandy","year":"2024","unstructured":"Chandy, M., & Conklin, D. J. (2024). Recent advances in the cardiotoxicity of anti-cancer drugs: Navigating the landscape of anthracycline-induced cardiotoxicity. Toxicology and Applied Pharmacology, 482, Article 116791.","journal-title":"Toxicology and Applied Pharmacology"},{"issue":"5","key":"10104_CR14","doi-asserted-by":"publisher","DOI":"10.31083\/j.rcm2405148","volume":"24","author":"A Ferrera","year":"2023","unstructured":"Ferrera, A., Fiorentini, V., Reale, S., Solfanelli, G., Tini, G., Barbato, E., et al. (2023). Anthracyclines-induced cardiac dysfunction: What every clinician should know. Reviews in Cardiovascular Medicine, 24(5), Article 148.","journal-title":"Reviews in Cardiovascular Medicine"},{"key":"10104_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/jcdd12060212","author":"L Spadafora","year":"2025","unstructured":"Spadafora, L., Di Muro, F. M., Intonti, C., Massa, L., Monelli, M., Pedretti, R. F., et al. (2025). Lifestyle and pharmacological interventions to prevent anthracycline-related cardiotoxicity in cancer patients. Journal of Cardiovascular Development and Disease. https:\/\/doi.org\/10.3390\/jcdd12060212","journal-title":"Journal of Cardiovascular Development and Disease"},{"key":"10104_CR16","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/8863789","volume":"2021","author":"R Carrasco","year":"2021","unstructured":"Carrasco, R., Castillo, R. L., Gormaz, J. G., Carrillo, M., & Thavendiranathan, P. (2021). Role of oxidative stress in the mechanisms of anthracycline-induced cardiotoxicity: Effects of preventive strategies. Oxidative Medicine and Cellular Longevity, 2021, Article 8863789.","journal-title":"Oxidative Medicine and Cellular Longevity"},{"key":"10104_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.811406","volume":"13","author":"J Huang","year":"2022","unstructured":"Huang, J., Wu, R., Chen, L., Yang, Z., Yan, D., & Li, M. (2022). Understanding anthracycline cardiotoxicity from mitochondrial aspect. Frontiers in Pharmacology, 13, Article 811406.","journal-title":"Frontiers in Pharmacology"},{"key":"10104_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.117312","volume":"179","author":"H Li","year":"2024","unstructured":"Li, H., Wang, M., & Huang, Y. (2024). Anthracycline-induced cardiotoxicity: An overview from cellular structural perspective. Biomedicine & Pharmacotherapy, 179, Article 117312.","journal-title":"Biomedicine & Pharmacotherapy"},{"issue":"5","key":"10104_CR19","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1007\/s12012-025-09986-2","volume":"25","author":"LA Kattan","year":"2025","unstructured":"Kattan, L. A., Abulola, S. M., Mohamed Ibrahim, M. I., & Maayah, Z. H. (2025). Anthracyclines-induced vascular endothelial dysfunction in cancer patients and survivors using brachial flow-mediated dilation (FMD) tool: A systematic review and meta-analysis. Cardiovascular Toxicology, 25(5), 692\u2013718.","journal-title":"Cardiovascular Toxicology"},{"key":"10104_CR20","doi-asserted-by":"publisher","first-page":"106777","DOI":"10.1016\/j.phrs.2023.106777","volume":"191","author":"X Zhang","year":"2023","unstructured":"Zhang, X., Yu, S., Li, X., Wen, X., Liu, S., Zu, R., et al. (2023). Research progress on the interaction between oxidative stress and platelets: Another avenue for cancer? Pharmacological Research, 191, 106777.","journal-title":"Pharmacological Research"},{"key":"10104_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/antiox11061194","author":"J Ho","year":"2022","unstructured":"Ho, J., Chaiswing, L., & St Clair, D. K. (2022). Extracellular vesicles and cancer therapy: Insights into the role of oxidative stress. Antioxidants. https:\/\/doi.org\/10.3390\/antiox11061194","journal-title":"Antioxidants"},{"key":"10104_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2022.108116","volume":"237","author":"JD Terwoord","year":"2022","unstructured":"Terwoord, J. D., Beyer, A. M., & Gutterman, D. D. (2022). Endothelial dysfunction as a complication of anti-cancer therapy. Pharmacology & Therapeutics, 237, Article 108116.","journal-title":"Pharmacology & Therapeutics"},{"key":"10104_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.817977","volume":"8","author":"S Antoniak","year":"2021","unstructured":"Antoniak, S., Phungphong, S., Cheng, Z., & Jensen, B. C. (2021). Novel mechanisms of anthracycline-induced cardiovascular toxicity: A focus on thrombosis, cardiac atrophy, and programmed cell death. Frontiers in Cardiovascular Medicine, 8, Article 817977.","journal-title":"Frontiers in Cardiovascular Medicine"},{"issue":"2","key":"10104_CR24","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1182\/blood-2015-01-624023","volume":"126","author":"J Etulain","year":"2015","unstructured":"Etulain, J., Martinod, K., Wong, S. L., Cifuni, S. M., Schattner, M., & Wagner, D. D. (2015). P-selectin promotes neutrophil extracellular trap formation in mice. Blood, 126(2), 242\u2013246.","journal-title":"Blood"},{"key":"10104_CR25","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.atherosclerosis.2020.04.018","volume":"307","author":"WC Schrottmaier","year":"2020","unstructured":"Schrottmaier, W. C., Mussbacher, M., Salzmann, M., & Assinger, A. (2020). Platelet-leukocyte interplay during vascular disease. Atherosclerosis, 307, 109\u201320.","journal-title":"Atherosclerosis"},{"key":"10104_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16132474","author":"I Konstantinidis","year":"2024","unstructured":"Konstantinidis, I., Tsokkou, S., Grigoriadis, S., Chrysavgi, L., & Gavriilaki, E. (2024). Cardiotoxicity in acute myeloid leukemia in adults: A scoping study. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers16132474","journal-title":"Cancers (Basel)"},{"key":"10104_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13050966","author":"R Di Francia","year":"2021","unstructured":"Di Francia, R., Crisci, S., De Monaco, A., Cafiero, C., Re, A., Iaccarino, G., et al. (2021). Response and toxicity to cytarabine therapy in leukemia and lymphoma: From dose puzzle to pharmacogenomic biomarkers. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers13050966","journal-title":"Cancers (Basel)"},{"issue":"9","key":"10104_CR28","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1159\/000365536","volume":"37","author":"S Baumann","year":"2014","unstructured":"Baumann, S., Huseynov, A., Goranova, D., Faust, M., Behnes, M., Nolte, F., et al. (2014). Takotsubo cardiomyopathy after systemic consolidation therapy with High-Dose intravenous cytarabine in a patient with acute myeloid leukemia. Oncology Research and Treatment, 37(9), 487\u201390.","journal-title":"Oncology Research and Treatment"},{"key":"10104_CR29","doi-asserted-by":"publisher","first-page":"xi166","DOI":"10.1016\/S0923-7534(20)32537-0","volume":"23","author":"Y Kikukawa","year":"2012","unstructured":"Kikukawa, Y., Watanabe, Y., Shimomura, T., & Suzushima, H. (2012). P3-166-4 cases of acute cardiac dysfunction induced by High-Dose cytarabine chemotherapy. Annals of Oncology, 23, xi166\u2013xi7.","journal-title":"Annals of Oncology"},{"issue":"25","key":"10104_CR30","doi-asserted-by":"publisher","first-page":"3122","DOI":"10.1161\/01.CIR.0000133187.74800.B9","volume":"109","author":"ETH Yeh","year":"2004","unstructured":"Yeh, E. T. H., Tong, A. T., Lenihan, D. J., Yusuf, S. W., Swafford, J., Champion, C., et al. (2004). Cardiovascular complications of cancer therapy. Circulation, 109(25), 3122\u201331.","journal-title":"Circulation"},{"issue":"1","key":"10104_CR31","doi-asserted-by":"publisher","DOI":"10.1590\/0001-3765202020190261","volume":"92","author":"AO Bilgin","year":"2020","unstructured":"Bilgin, A. O., Mammadov, R., Suleyman, B., Unver, E., Ozcicek, F., Soyturk, M., et al. (2020). Effect of rutin on cytarabine-associated pulmonary oedema and oxidative stress in rats. Anais da Academia Brasileira de Ciencias, 92(1), Article e20190261.","journal-title":"Anais da Academia Brasileira de Ciencias"},{"issue":"1","key":"10104_CR32","doi-asserted-by":"publisher","first-page":"50","DOI":"10.3109\/10428194.2011.616611","volume":"53","author":"N Shah","year":"2012","unstructured":"Shah, N., Cabanillas, F., McIntyre, B., Feng, L., McLaughlin, P., Rodriguez, M. A., et al. (2012). Prognostic value of serum CD44, intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 levels in patients with indolent non-Hodgkin lymphomas. Leukaemia & Lymphoma, 53(1), 50\u201356.","journal-title":"Leukaemia & Lymphoma"},{"issue":"6","key":"10104_CR33","doi-asserted-by":"publisher","first-page":"e13158","DOI":"10.1111\/sji.13158","volume":"95","author":"H Bai","year":"2022","unstructured":"Bai, H., Peng, Y., Li, Y., Duan, J., Fu, W., Liang, X., et al. (2022). Cytarabine-induced TNF\u03b1 promotes the expansion and suppressive functions of myeloid-derived suppressor cells in acute myeloid leukaemia. Scandinavian Journal of Immunology, 95(6), e13158.","journal-title":"Scandinavian Journal of Immunology"},{"issue":"21","key":"10104_CR34","doi-asserted-by":"publisher","first-page":"3246","DOI":"10.1182\/blood-2014-10-551507","volume":"125","author":"C R\u00f6llig","year":"2015","unstructured":"R\u00f6llig, C., & Ehninger, G. (2015). How i treat hyperleukocytosis in acute myeloid leukemia. Blood, 125(21), 3246\u20133252.","journal-title":"Blood"},{"issue":"9","key":"10104_CR35","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1111\/j.1538-7836.2005.01467.x","volume":"3","author":"V De Stefano","year":"2005","unstructured":"De Stefano, V., Sor\u00c0, F., Rossi, E., Chiusolo, P., Laurenti, L., Fianchi, L., et al. (2005). The risk of thrombosis in patients with acute leukemia: Occurrence of thrombosis at diagnosis and during treatment. Journal of Thrombosis and Haemostasis, 3(9), 1985\u20131992.","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"3","key":"10104_CR36","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1159\/000512771","volume":"146","author":"EV Grakova","year":"2021","unstructured":"Grakova, E. V., Shilov, S. N., Kopeva, K. V., Berezikova, E. N., Popova, A. A., Neupokoeva, M. N., et al. (2021). Anthracycline-induced cardiotoxicity: The role of endothelial dysfunction. Cardiology, 146(3), 315\u201323.","journal-title":"Cardiology"},{"issue":"5","key":"10104_CR37","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.ekir.2022.02.014","volume":"7","author":"H Izzedine","year":"2022","unstructured":"Izzedine, H., Mathian, A., Amoura, Z., Ng, J. H., & Jhaveri, K. D. (2022). Anticancer drug-induced capillary leak syndrome. Kidney International Reports, 7(5), 945\u201353.","journal-title":"Kidney International Reports"},{"key":"10104_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2023.103984","volume":"185","author":"RM Lemoli","year":"2023","unstructured":"Lemoli, R. M., Montesinos, P., & Jain, A. (2023). Real-world experience with CPX-351 in high-risk acute myeloid leukemia. Critical Reviews in Oncology\/Hematology, 185, Article 103984.","journal-title":"Critical Reviews in Oncology\/Hematology"},{"issue":"7","key":"10104_CR39","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/s40265-025-02194-w","volume":"85","author":"L Pagano","year":"2025","unstructured":"Pagano, L., Danesi, R., Benedetti, E., Morgagni, R., Romani, L., & Venditti, A. (2025). The role of CPX-351 in the acute myeloid leukemia treatment landscape: Mechanism of action, efficacy, and safety. Drugs, 85(7), 855\u2013866.","journal-title":"Drugs"},{"issue":"5","key":"10104_CR40","doi-asserted-by":"publisher","DOI":"10.1002\/cnr2.70199","volume":"8","author":"AM Alzahrani","year":"2025","unstructured":"Alzahrani, A. M., Alnuhait, M. A., & Alqahtani, T. (2025). The clinical safety and efficacy of cytarabine and daunorubicin liposome (CPX-351) in acute myeloid leukemia patients: A systematic review. Cancer Reports (Hoboken), 8(5), Article e70199.","journal-title":"Cancer Reports (Hoboken)"},{"key":"10104_CR41","doi-asserted-by":"publisher","first-page":"1347547","DOI":"10.3389\/fcvm.2024.1347547","volume":"11","author":"KJ Leger","year":"2024","unstructured":"Leger, K. J., Absalon, M. J., Demissei, B. G., Smith, A. M., Gerbing, R. B., Alonzo, T. A., et al. (2024). Cardiotoxicity of CPX-351 in children and adolescents with relapsed AML: A children\u2019s oncology group report. Frontiers in Cardiovascular Medicine, 11, 1347547.","journal-title":"Frontiers in Cardiovascular Medicine"},{"issue":"1","key":"10104_CR42","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1182\/bloodadvances.2020003159","volume":"5","author":"E Chiche","year":"2021","unstructured":"Chiche, E., Rahm\u00e9, R., Bertoli, S., Dumas, P-Y., Micol, J-B., Hicheri, Y., et al. (2021). Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: A multicentric French cohort. Blood Advances, 5(1), 176\u2013184.","journal-title":"Blood Advances"},{"issue":"18","key":"10104_CR43","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1007\/s40265-018-1022-3","volume":"78","author":"HA Blair","year":"2018","unstructured":"Blair, H. A. (2018). Daunorubicin\/Cytarabine liposome: A review in acute myeloid leukaemia. Drugs, 78(18), 1903\u201310.","journal-title":"Drugs"},{"key":"10104_CR44","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14122843","author":"M Molica","year":"2022","unstructured":"Molica, M., Perrone, S., Mazzone, C., Cesini, L., Canichella, M., & de Fabritiis, P. (2022). CPX-351: An old scheme with a new formulation in the treatment of high-risk AML. Cancers. https:\/\/doi.org\/10.3390\/cancers14122843","journal-title":"Cancers"},{"issue":"5","key":"10104_CR45","doi-asserted-by":"publisher","first-page":"739","DOI":"10.3892\/etm.2010.127","volume":"1","author":"D Panigrahy","year":"2010","unstructured":"Panigrahy, D., Kaipainen, A., Butterfield, C. E., Chaponis, D. M., Laforme, A. M., Folkman, J., et al. (2010). Inhibition of tumor angiogenesis by oral etoposide. Experimental and Therapeutic Medicine, 1(5), 739\u201346.","journal-title":"Experimental and Therapeutic Medicine"},{"issue":"6","key":"10104_CR46","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0005859","volume":"4","author":"A Muslimovi\u0107","year":"2009","unstructured":"Muslimovi\u0107, A., Nystr\u00f6m, S., Gao, Y., & Hammarsten, O. (2009). Numerical analysis of etoposide induced DNA breaks. PLoS One, 4(6), Article e5859.","journal-title":"PLoS One"},{"issue":"1","key":"10104_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/srep34064","volume":"6","author":"H-J Shin","year":"2016","unstructured":"Shin, H.-J., Kwon, H.-K., Lee, J.-H., Anwar, M. A., & Choi, S. (2016). Etoposide induced cytotoxicity mediated by ROS and ERK in human kidney proximal tubule cells. Scientific Reports, 6(1), Article 34064.","journal-title":"Scientific Reports"},{"issue":"25","key":"10104_CR48","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.1182\/blood.2023023179","volume":"144","author":"R Xue","year":"2024","unstructured":"Xue, R., Li, M., Zhang, G., Zhang, W., Han, L., Bo, T., et al. (2024). GSDME-mediated pyroptosis contributes to chemotherapy-induced platelet hyperactivity and thrombotic potential. Blood, 144(25), 2652\u20132665.","journal-title":"Blood"},{"key":"10104_CR49","doi-asserted-by":"publisher","DOI":"10.1200\/GO.23.00165","volume":"10","author":"MK Al-Khabori","year":"2024","unstructured":"Al-Khabori, M. K., Alhuraiji, A., Alam, A. R., Khan, F. A., El Omri, H., Osman, H. Y., AaL Yaseen, H. M., Al Bulushi, M. P., Pandita, R. K., & Marashi, M. M. (2024). Consensus-based guidelines for acute myeloid leukemia management in Gulf cooperation council countries: Addressing unmet regional needs and the changing AML landscape. JCO Global Oncology, 10, Article e2300165.","journal-title":"JCO Global Oncology"},{"key":"10104_CR50","doi-asserted-by":"publisher","first-page":"16","DOI":"10.6004\/jnccn.2021.0002","volume":"19","author":"DABD Pollyea","year":"2021","unstructured":"Pollyea, D. A. B. D., Perl, A., Bhatt, V. R., Altman, J. K., Appelbaum, F. R., de Lima, M., Fathi, A. T., Foran, J. M., Gojo, I., & Hall, A. C. (2021). NCCN guidelines insights: acute myeloid leukemia, version 2.2021: Featured updates to the NCCN guidelines. Journal of the National Comprehensive Cancer Network, 19, 16\u201327.","journal-title":"Journal of the National Comprehensive Cancer Network"},{"issue":"9","key":"10104_CR51","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1182\/bloodadvances.2024013744","volume":"9","author":"A Venditti","year":"2025","unstructured":"Venditti, A., Palmieri, R., Maurillo, L., R\u00f6llig, C., Wierzbowska, A., de Leeuw, D., Efficace, F., Curti, A., Ngai, L. L., Tettero, J., & Ad\u00e8s, L. (2025). Fitness assessment in acute myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood Advances, 9(9), 2207\u20132220.","journal-title":"Blood Advances"},{"key":"10104_CR52","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"HWA D\u00f6hner","year":"2022","unstructured":"D\u00f6hner, H. W. A., Appelbaum, F. R., Craddock, C., DiNardo, C. D., Dombret, H., Ebert, B. L., Fenaux, P., Godley, L. A., Hasserjian, R. P., & Larson, R. A. (2022). Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood, 140, 1345\u20131377.","journal-title":"Blood"},{"key":"10104_CR53","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11020641","author":"TM Totiger","year":"2023","unstructured":"Totiger, T. M., Ghoshal, A., Zabroski, J., Sondhi, A., Bucha, S., Jahn, J., et al. (2023). Targeted therapy development in acute myeloid leukemia. Biomedicines. https:\/\/doi.org\/10.3390\/biomedicines11020641","journal-title":"Biomedicines"},{"key":"10104_CR54","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3390\/cancers13184646","volume":"13","author":"K Ahmadmehrabi","year":"2021","unstructured":"Ahmadmehrabi, K., Haque, A. R., Aleem, A., Griffiths, E. A., & Roloff, G. W. (2021). Targeted therapies for the evolving molecular landscape of acute myeloid leukemia. Cancers (Basel), 13, 18.","journal-title":"Cancers (Basel)"},{"key":"10104_CR55","doi-asserted-by":"publisher","first-page":"116585","DOI":"10.1016\/j.taap.2023.116585","volume":"473","author":"RH Wu","year":"2023","unstructured":"Wu, R. H., Zhu, C. Y., Yu, P. H., Ma, Y., Hussain, L., Naranmandura, H., et al. (2023). The landscape of novel strategies for acute myeloid leukemia treatment: Therapeutic trends, challenges, and future directions. Toxicology and Applied Pharmacology, 473, 116585.","journal-title":"Toxicology and Applied Pharmacology"},{"issue":"5","key":"10104_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2025.104367","volume":"30","author":"Q-Y Rong","year":"2025","unstructured":"Rong, Q.-Y., Lu, Y., Zhang, W., Rao, G.-W., & Zheng, Q. (2025). Targeting FLT3 for treating diseases: FLT3 inhibitors. Drug Discovery Today, 30(5), Article 104367.","journal-title":"Drug Discovery Today"},{"issue":"2","key":"10104_CR57","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1161\/ATVBAHA.119.313353","volume":"40","author":"A Manouchehri","year":"2020","unstructured":"Manouchehri, A., Kanu, E., Mauro, M. J., Aday, A. W., Lindner, J. R., & Moslehi, J. (2020). Tyrosine kinase inhibitors in leukemia and cardiovascular events. Arteriosclerosis, Thrombosis, and Vascular Biology, 40(2), 301\u2013308.","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"issue":"11","key":"10104_CR58","doi-asserted-by":"publisher","DOI":"10.1111\/cts.70065","volume":"17","author":"P Vaddady","year":"2024","unstructured":"Vaddady, P., Smania, G., Nakayama, S., Inoue, H., Kurumaddali, A., Abutarif, M., et al. (2024). Concentration-QTcF analysis of quizartinib in patients with newly diagnosed FLT3-internal-tandem-duplication-positive acute myeloid leukemia. Clinical and Translational Science, 17(11), Article e70065.","journal-title":"Clinical and Translational Science"},{"issue":"4","key":"10104_CR59","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1111\/ejh.14383","volume":"114","author":"A Bruzzese","year":"2025","unstructured":"Bruzzese, A., Martino, E. A., Labanca, C., Mendicino, F., Lucia, E., Olivito, V., et al. (2025). Advances and challenges in Quizartinib-based FLT3 Inhibition for acute myeloid leukemia: Mechanisms of resistance and prospective combination therapies. European Journal of Haematology, 114(4), 584\u2013595.","journal-title":"European Journal of Haematology"},{"issue":"23","key":"10104_CR60","doi-asserted-by":"publisher","first-page":"3366","DOI":"10.1182\/blood.2021011583","volume":"139","author":"AE Perl","year":"2022","unstructured":"Perl, A. E., Larson, R. A., Podoltsev, N. A., Strickland, S., Wang, E. S., Atallah, E., et al. (2022). Follow-up of patients with R\/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial. Blood, 139(23), 3366\u20133375.","journal-title":"Blood"},{"issue":"6","key":"10104_CR61","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1038\/s41375-023-01897-x","volume":"37","author":"Y Jia","year":"2023","unstructured":"Jia, Y., Zhang, W., Basyal, M., Chang, K. H., Ostermann, L., Burks, J. K., et al. (2023). FLT3 inhibitors upregulate CXCR4 and E-selectin ligands via ERK suppression in AML cells and CXCR4\/E-selectin Inhibition enhances anti-leukemia efficacy of FLT3-targeted therapy in AML. Leukemia, 37(6), 1379\u20131383.","journal-title":"Leukemia"},{"key":"10104_CR62","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14174315","author":"D Capelli","year":"2022","unstructured":"Capelli, D., Menotti, D., Fiorentini, A., Saraceni, F., & Olivieri, A. (2022). Overcoming resistance: FLT3 inhibitors past, present, future and the challenge of cure. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers14174315","journal-title":"Cancers (Basel)"},{"issue":"Supplement 1","key":"10104_CR63","doi-asserted-by":"publisher","first-page":"6183","DOI":"10.1182\/blood-2022-169932","volume":"140","author":"V Dhillon","year":"2022","unstructured":"Dhillon, V., Khan, A. M., Sbihi, A. A., Nanja Reddy, S., Lalo, E., Ramos, H., et al. (2022). Real-World outcomes and cardiac implications of FLT3 inhibitors in acute myeloid leukemia. Blood, 140(Supplement 1), 6183\u20136184.","journal-title":"Blood"},{"issue":"1","key":"10104_CR64","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1161\/ATVBAHA.120.314694","volume":"41","author":"MD Wu","year":"2021","unstructured":"Wu, M. D., Moslehi, J. J., & Lindner, J. R. (2021). Arterial thrombotic complications of tyrosine kinase inhibitors. Arteriosclerosis, Thrombosis, and Vascular Biology, 41(1), 3\u201310.","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"issue":"12","key":"10104_CR65","doi-asserted-by":"publisher","first-page":"3091","DOI":"10.1038\/s41409-021-01475-8","volume":"56","author":"EC Liang","year":"2021","unstructured":"Liang, E. C., Chen, C., Lu, R., Mannis, G. N., & Muffly, L. (2021). Measurable residual disease status and FLT3 inhibitor therapy in patients with FLT3-ITD mutated AML following allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation, 56(12), 3091\u20133.","journal-title":"Bone Marrow Transplantation"},{"issue":"6","key":"10104_CR66","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1007\/s00401-016-1620-7","volume":"132","author":"D Unruh","year":"2016","unstructured":"Unruh, D., Schwarze, S. R., Khoury, L., Thomas, C., Wu, M., Chen, L., et al. (2016). Mutant IDH1 and thrombosis in gliomas. Acta Neuropathologica, 132(6), 917\u201330.","journal-title":"Acta Neuropathologica"},{"issue":"7","key":"10104_CR67","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1177\/2040620718777467","volume":"9","author":"I Abou Dalle","year":"2018","unstructured":"Abou Dalle, I., & DiNardo, C. D. (2018). The role of enasidenib in the treatment of mutant IDH2 acute myeloid leukemia. Therapeutic Advances in Hematology, 9(7), 163\u2013173.","journal-title":"Therapeutic Advances in Hematology"},{"issue":"6","key":"10104_CR68","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1111\/jth.14129","volume":"16","author":"P Mir Seyed Nazari","year":"2018","unstructured":"Mir Seyed Nazari, P., Riedl, J., Preusser, M., Posch, F., Thaler, J., Marosi, C., et al. (2018). Combination of isocitrate dehydrogenase 1 (IDH1) mutation and Podoplanin expression in brain tumors identifies patients at high or low risk of venous thromboembolism. Journal of Thrombosis and Haemostasis, 16(6), 1121\u20131127.","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10104_CR69","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-019-0173-z","volume":"7","author":"X Liu","year":"2019","unstructured":"Liu, X., & Gong, Y. (2019). Isocitrate dehydrogenase inhibitors in acute myeloid leukemia. Biomarker Research, 7, Article 22.","journal-title":"Biomarker Research"},{"issue":"14","key":"10104_CR70","doi-asserted-by":"publisher","first-page":"3456","DOI":"10.3390\/cancers14143456","volume":"14","author":"MS Griffioen","year":"2022","unstructured":"Griffioen, M. S., de Leeuw, D. C., Janssen, J., & Smit, L. (2022). Targeting acute myeloid leukemia with venetoclax; biomarkers for sensitivity and rationale for venetoclax-based combination therapies. Cancers (Basel), 14(14), 3456.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10104_CR71","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s40959-024-00275-5","volume":"10","author":"T Onoue","year":"2024","unstructured":"Onoue, T., Matthews, A. H., Vakilpour, A., Kang, Y., Lefebvre, B., Smith, A. M., et al. (2024). Cardiotoxicity of venetoclax in patients with acute myeloid leukemia: Comparison with anthracyclines. Cardio-Oncology, 10(1), 75.","journal-title":"Cardio-Oncology"},{"key":"10104_CR72","doi-asserted-by":"publisher","DOI":"10.3390\/reports7040108","author":"R Fankhauser","year":"2024","unstructured":"Fankhauser, R., Lu, A., Kassim, A., & Biltibo, E. (2024). Tumor lysis syndrome with venetoclax\/carfilzomib\/dexamethasone for relapsed\/refractory multiple myeloma: A case report. Reports. https:\/\/doi.org\/10.3390\/reports7040108","journal-title":"Reports"},{"issue":"8","key":"10104_CR73","doi-asserted-by":"publisher","first-page":"564","DOI":"10.2174\/0113892002338926241114080504","volume":"25","author":"Y Yan","year":"2025","unstructured":"Yan, Y., Guo, Y., Wang, Z., He, W., Zhu, Y., Zhao, X., et al. (2025). Clinical Pharmacology and side effects of venetoclax in hematologic malignancies. Current Drug Metabolism, 25(8), 564\u2013575.","journal-title":"Current Drug Metabolism"},{"issue":"9","key":"10104_CR74","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6806","volume":"13","author":"C Fan","year":"2024","unstructured":"Fan, C., Yang, X., Yan, L., & Shi, Z. (2024). Oxidative stress is two-sided in the treatment of acute myeloid leukemia. Cancer Medicine, 13(9), Article e6806.","journal-title":"Cancer Medicine"},{"key":"10104_CR75","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102261","author":"A Kojic","year":"2025","unstructured":"Kojic, A., Moslehi, J., Ky, B., & Wu, J. C. (2025). Cardiometabolic disease and cardio-oncology: Insights from iPSC models and tissue engineering. Cell Reports Medicine. https:\/\/doi.org\/10.1016\/j.xcrm.2025.102261","journal-title":"Cell Reports Medicine"},{"key":"10104_CR76","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcha.2025.101756","volume":"60","author":"Z Wei","year":"2025","unstructured":"Wei, Z., Ahmad, M., Chen, R., Fatima, S., & Shah, S. (2025). High-intensity interval training improves mitochondrial function and attenuates cardiomyocytes damage in ischemia-reperfusion. IJC Heart & Vasculature, 60, Article 101756.","journal-title":"IJC Heart & Vasculature"},{"issue":"3","key":"10104_CR77","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1152\/physrev.00026.2013","volume":"94","author":"DB Zorov","year":"2014","unstructured":"Zorov, D. B., Juhaszova, M., & Sollott, S. J. (2014). Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release. Physiological Reviews, 94(3), 909\u201350.","journal-title":"Physiological Reviews"},{"issue":"10","key":"10104_CR78","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1161\/01.RES.0000148632.35500.d9","volume":"95","author":"MT Crow","year":"2004","unstructured":"Crow, M. T., Mani, K., Nam, Y.-J., & Kitsis, R. N. (2004). The mitochondrial death pathway and cardiac myocyte apoptosis. Circulation Research, 95(10), 957\u201370.","journal-title":"Circulation Research"},{"key":"10104_CR79","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19113480","author":"J Marinello","year":"2018","unstructured":"Marinello, J., Delcuratolo, M., & Capranico, G. (2018). Anthracyclines as topoisomerase II poisons: From early studies to new perspectives. International Journal of Molecular Sciences. https:\/\/doi.org\/10.3390\/ijms19113480","journal-title":"International Journal of Molecular Sciences"},{"issue":"1\u20132","key":"10104_CR80","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/aac2.12033","volume":"2","author":"ZS Clayton","year":"2021","unstructured":"Clayton, Z. S., Hutton, D. A., Mahoney, S. A., & Seals, D. R. (2021). Anthracycline chemotherapy-mediated vascular dysfunction as a model of accelerated vascular aging. Aging Cancer, 2(1\u20132), 45\u201369.","journal-title":"Aging Cancer"},{"key":"10104_CR81","doi-asserted-by":"publisher","first-page":"873898","DOI":"10.3389\/fcvm.2022.873898","volume":"9","author":"C Schneider","year":"2022","unstructured":"Schneider, C., Gonz\u00e1lez-Jaramillo, N., Marcin, T., Campbell, K. L., Suter, T., & Bano, A. (2022). Time-dependent effect of anthracycline-based chemotherapy on central arterial stiffness: A systematic review and meta-analysis. Frontiers in Cardiovascular Medicine, 9, 873898.","journal-title":"Frontiers in Cardiovascular Medicine"},{"issue":"14","key":"10104_CR82","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.015598","volume":"9","author":"SK Parr","year":"2020","unstructured":"Parr, S. K., Liang, J., Schadler, K. L., Gilchrist, S. C., Steele, C. C., & Ade, C. J. (2020). Anticancer therapy\u2013related increases in arterial stiffness: A systematic review and meta-analysis. Journal of the American Heart Association, 9(14), Article e015598.","journal-title":"Journal of the American Heart Association"},{"issue":"3","key":"10104_CR83","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1161\/CIRCRESAHA.107.151860b","volume":"101","author":"RM Rao","year":"2007","unstructured":"Rao, R. M., Yang, L., Garcia-Cardena, G., & Luscinskas, F. W. (2007). Endothelial-dependent mechanisms of leukocyte recruitment to the vascular wall. Circulation Research, 101(3), 234\u201347.","journal-title":"Circulation Research"},{"issue":"11","key":"10104_CR84","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1038\/nri3908","volume":"15","author":"D Vestweber","year":"2015","unstructured":"Vestweber, D. (2015). How leukocytes cross the vascular endothelium. Nature Reviews Immunology, 15(11), 692\u2013704.","journal-title":"Nature Reviews Immunology"},{"issue":"3","key":"10104_CR85","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s00262-021-03013-3","volume":"71","author":"N Behranvand","year":"2022","unstructured":"Behranvand, N., Nasri, F., Zolfaghari Emameh, R., Khani, P., Hosseini, A., Garssen, J., et al. (2022). Chemotherapy: A double-edged sword in cancer treatment. Cancer Immunology, Immunotherapy, 71(3), 507\u2013526.","journal-title":"Cancer Immunology, Immunotherapy"},{"issue":"5","key":"10104_CR86","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1007\/s00277-023-05158-w","volume":"102","author":"T Hellou","year":"2023","unstructured":"Hellou, T., Cohen, O., Avigdor, A., Amitai, I., Shimoni, A., Misgav, M., et al. (2023). The occurrence of thrombosis during intensive chemotherapy treatment for acute myeloid leukemia patients does not impact on long-term survival. Annals of Hematology, 102(5), 1037\u201343.","journal-title":"Annals of Hematology"},{"key":"10104_CR87","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15113060","author":"M Mitrovic","year":"2023","unstructured":"Mitrovic, M., Pantic, N., Sabljic, N., Bukumiric, Z., Virijevic, M., Pravdic, Z., et al. (2023). Arterial thrombosis in patients with acute myeloid leukemia: Incidence and risk factors. Cancers. https:\/\/doi.org\/10.3390\/cancers15113060","journal-title":"Cancers"},{"issue":"Supplement 1","key":"10104_CR88","doi-asserted-by":"publisher","first-page":"5809","DOI":"10.1182\/blood-2024-210121","volume":"144","author":"X Liang","year":"2024","unstructured":"Liang, X., Wang, H., Zhou, J., Zhu, J., Jiao, X., & Zhai, Z. (2024). Platelets form aggregates on the surface of AML cells via CD62P\/PSGL-1 and release TGF-\u03b21 to promote drug resistance. Blood, 144(Supplement 1), 5809.","journal-title":"Blood"},{"key":"10104_CR89","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvaf105","author":"J Han","year":"2025","unstructured":"Han, J., Bloxham, C. J., Kirmes, K., Viggiani, G., Unkelbach, L. P., von Scheidt, M., et al. (2025). Platelet\u2013leukocyte aggregates in cardiovascular disease: Prognostic significance and therapeutic potential. Cardiovascular Research. https:\/\/doi.org\/10.1093\/cvr\/cvaf105","journal-title":"Cardiovascular Research"},{"issue":"1","key":"10104_CR90","doi-asserted-by":"publisher","DOI":"10.1186\/s12645-025-00340-3","volume":"16","author":"J Naghinezhad","year":"2025","unstructured":"Naghinezhad, J., Moradpanah, S., Khodakarim, N., Hamblin, M. R., & Rezaeeyan, H. (2025). Nanodrug-based modulation of platelet\u2013leukocyte interactions in ovarian cancer: A new frontier in targeted therapy. Cancer Nanotechnology, 16(1), Article 37.","journal-title":"Cancer Nanotechnology"},{"key":"10104_CR91","doi-asserted-by":"publisher","first-page":"1377806","DOI":"10.3389\/frhem.2024.1377806","volume":"3","author":"D Aydemir","year":"2024","unstructured":"Aydemir, D. (2024). The impact of NETosis on hematological malignancies as a promising therapeutic target. Frontiers in Hematology, 3, 1377806.","journal-title":"Frontiers in Hematology"},{"issue":"18","key":"10104_CR92","doi-asserted-by":"publisher","first-page":"3965","DOI":"10.1158\/1078-0432.CCR-24-1363","volume":"30","author":"YM Mowery","year":"2024","unstructured":"Mowery, Y. M., & Luke, J. J. (2024). NETosis impact on tumor biology, radiation, and systemic therapy resistance. Clinical Cancer Research, 30(18), 3965\u20137.","journal-title":"Clinical Cancer Research"},{"issue":"1","key":"10104_CR93","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s12959-023-00512-4","volume":"21","author":"W Li","year":"2023","unstructured":"Li, W., Wang, Z., Cg, S., Liao, Z., Pei, Y., Wang, J., et al. (2023). The effect of neutrophil extracellular traps in venous thrombosis. Thrombosis Journal, 21(1), 67.","journal-title":"Thrombosis Journal"},{"key":"10104_CR94","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00928","volume":"8","author":"H Qi","year":"2017","unstructured":"Qi, H., Yang, S., & Zhang, L. (2017). Neutrophil extracellular traps and endothelial dysfunction in atherosclerosis and thrombosis. Frontiers in Immunology, 8, Article 928.","journal-title":"Frontiers in Immunology"},{"issue":"7","key":"10104_CR95","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1016\/j.jtha.2024.03.020","volume":"22","author":"Y Hisada","year":"2024","unstructured":"Hisada, Y., Archibald, S. J., Bansal, K., Chen, Y., Dai, C., Dwarampudi, S., et al. (2024). Biomarkers of bleeding and venous thromboembolism in patients with acute leukemia. Journal of Thrombosis and Haemostasis, 22(7), 1984\u20131996.","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10104_CR96","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12041612","author":"C Mauro","year":"2023","unstructured":"Mauro, C., Capone, V., Cocchia, R., Cademartiri, F., Riccardi, F., Arcopinto, M., et al. (2023). Exploring the cardiotoxicity spectrum of anti-cancer treatments: Definition, classification, and diagnostic pathways. Journal of Clinical Medicine. https:\/\/doi.org\/10.3390\/jcm12041612","journal-title":"Journal of Clinical Medicine"},{"issue":"1","key":"10104_CR97","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1161\/CIRCRESAHA.109.206920","volume":"106","author":"H Cheng","year":"2010","unstructured":"Cheng, H., & Force, T. (2010). Molecular mechanisms of cardiovascular toxicity of targeted cancer therapeutics. Circulation Research, 106(1), 21\u201334.","journal-title":"Circulation Research"},{"key":"10104_CR98","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15030986","author":"G S\u0142awi\u0144ski","year":"2023","unstructured":"S\u0142awi\u0144ski, G., Hawryszko, M., Li\u017cewska-Springer, A., Nabia\u0142ek-Trojanowska, I., & Lewicka, E. (2023). Global longitudinal strain in cardio-oncology: A review. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers15030986","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10104_CR99","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.113.000665","volume":"3","author":"VS Hahn","year":"2014","unstructured":"Hahn, V. S., Lenihan, D. J., & Ky, B. (2014). Cancer therapy\u2013induced cardiotoxicity: Basic mechanisms and potential cardioprotective therapies. Journal of the American Heart Association, 3(2), Article e000665.","journal-title":"Journal of the American Heart Association"},{"issue":"12","key":"10104_CR100","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1007\/s11886-024-02131-5","volume":"26","author":"E Hutchins","year":"2024","unstructured":"Hutchins, E., Yang, E. H., & Stein-Merlob, A. F. (2024). Inflammation in chemotherapy-induced cardiotoxicity. Current Cardiology Reports, 26(12), 1329\u20131340.","journal-title":"Current Cardiology Reports"},{"issue":"11","key":"10104_CR101","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1161\/CIRCRESAHA.120.315894","volume":"128","author":"AH Baik","year":"2021","unstructured":"Baik, A. H., Oluwole, O. O., Johnson, D. B., Shah, N., Salem, J.-E., Tsai, K. K., et al. (2021). Mechanisms of cardiovascular toxicities associated with immunotherapies. Circulation Research, 128(11), 1780\u2013801.","journal-title":"Circulation Research"},{"issue":"8","key":"10104_CR102","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70188","volume":"9","author":"AM Baumann","year":"2025","unstructured":"Baumann, A. M., & Ellegast, J. M. (2025). Inflammatory signaling in the pathogenesis of acute myeloid leukemia. Hemasphere, 9(8), Article e70188.","journal-title":"Hemasphere"},{"issue":"8","key":"10104_CR103","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCEP.117.005443","volume":"10","author":"V Buza","year":"2017","unstructured":"Buza, V., Rajagopalan, B., & Curtis, A. B. (2017). Cancer treatment\u2013induced arrhythmias. Circulation. Arrhythmia and Electrophysiology, 10(8), Article e005443.","journal-title":"Circulation. Arrhythmia and Electrophysiology"},{"issue":"10","key":"10104_CR104","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/j.amjmed.2021.05.026","volume":"134","author":"H Essa","year":"2021","unstructured":"Essa, H., Wright, D. J., Dobson, R., & Lip, G. Y. H. (2021). Chemotherapy-induced arrhythmia \u2013 Underrecognized and undertreated. The American Journal of Medicine, 134(10), 1224\u201331.e1.","journal-title":"The American Journal of Medicine"},{"key":"10104_CR105","doi-asserted-by":"publisher","DOI":"10.3390\/life12081183","author":"V Sorodoc","year":"2022","unstructured":"Sorodoc, V., Sirbu, O., Lionte, C., Haliga, R. E., Stoica, A., Ceasovschih, A., et al. (2022). The value of troponin as a biomarker of chemotherapy-induced cardiotoxicity. Life. https:\/\/doi.org\/10.3390\/life12081183","journal-title":"Life"},{"issue":"6","key":"10104_CR106","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/s11864-023-01089-w","volume":"24","author":"M Olivi","year":"2023","unstructured":"Olivi, M., Di Biase, F., Lanzarone, G., Arrigo, G., Martella, F., Apolito, V., et al. (2023). Thrombosis in acute myeloid leukemia: Pathogenesis, risk factors and therapeutic challenges. Current Treatment Options in Oncology, 24(6), 693\u2013710.","journal-title":"Current Treatment Options in Oncology"},{"issue":"2","key":"10104_CR107","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1634\/theoncologist.2016-0214","volume":"22","author":"E Donnellan","year":"2017","unstructured":"Donnellan, E., & Khorana, A. A. (2017). Cancer and venous thromboembolic disease: A review. Oncologist, 22(2), 199\u2013207.","journal-title":"Oncologist"},{"issue":"4","key":"10104_CR108","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1111\/ejh.13920","volume":"110","author":"SE Koschade","year":"2023","unstructured":"Koschade, S. E., Stratmann, J. A., Steffen, B., Shaid, S., Finkelmeier, F., Serve, H., et al. (2023). Early-onset venous thromboembolisms in newly diagnosed non-promyelocytic acute myeloid leukemia patients undergoing intensive induction chemotherapy. European Journal of Haematology, 110(4), 426\u201334.","journal-title":"European Journal of Haematology"},{"key":"10104_CR109","doi-asserted-by":"publisher","first-page":"3060","DOI":"10.3390\/cancers15113060","volume":"15","author":"M Mitrovic","year":"2023","unstructured":"Mitrovic, M., Panti\u0107, N., Sabljic, N., Bukumiric, Z., Virijevic, M., Pravdic, Z., et al. (2023). Arterial thrombosis in patients with acute myeloid leukemia: Incidence and risk factors. Cancers, 15, 3060.","journal-title":"Cancers"},{"key":"10104_CR110","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.786387","volume":"8","author":"Y Zhou","year":"2021","unstructured":"Zhou, Y., Tao, W., Shen, F., Du, W., Xu, Z., & Liu, Z. (2021). The emerging role of neutrophil extracellular traps in arterial, venous and cancer-associated thrombosis. Frontiers in Cardiovascular Medicine, 8, Article 786387.","journal-title":"Frontiers in Cardiovascular Medicine"},{"issue":"1","key":"10104_CR111","doi-asserted-by":"publisher","DOI":"10.1093\/omcr\/omy118","volume":"2019","author":"ASO Tang","year":"2019","unstructured":"Tang, A. S. O., Yeo, S. T., Law, W. C., & Chew, L. P. (2019). Cerebral venous thrombosis as an initial manifestation of acute myeloid leukemia. Oxford Medical Case Reports, 2019(1), Article omy118.","journal-title":"Oxford Medical Case Reports"},{"issue":"4","key":"10104_CR112","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1111\/bjh.70026","volume":"207","author":"RH Jensen","year":"2025","unstructured":"Jensen, R. H., Teglgaard, C., Jensen, J. F., Baech, J., Marcher, C. W., Roug, A. S., \u00d8rskov, A. D., Sch\u00f6llkopf, C., Kristensen, D. T., Br\u00f8ndum, R. F., & Severinsen, M. T. (2025). Cardiotoxicity in patients with acute myeloid leukaemia following anthracycline-containing chemotherapy: A population-based matched cohort study. British Journal of Haematology, 207(4), 1416\u20131424.","journal-title":"British Journal of Haematology"},{"key":"10104_CR113","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17030541","author":"KC Siaravas","year":"2025","unstructured":"Siaravas, K. C., Moula, A. I., Tzourtzos, I. S., Ballas, C. E., & Katsouras, C. S. (2025). Acute and chronic cardiovascular adverse events in patients with acute myeloid leukemia: A systematic review. Cancers. https:\/\/doi.org\/10.3390\/cancers17030541","journal-title":"Cancers"},{"issue":"5","key":"10104_CR114","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1007\/s11239-025-03085-3","volume":"58","author":"E Jalaber","year":"2025","unstructured":"Jalaber, E., Orvain, C., Papadopoulou, V., Genthon, A., Daguerre, V., Barri\u00e8re, S., et al. (2025). Management of thrombocytopenia and anticoagulant therapy in patients with hematological malignancy on chemotherapy: A binational prospective study (TAT study). Journal of Thrombosis and Thrombolysis, 58(5), 646\u201356.","journal-title":"Journal of Thrombosis and Thrombolysis"},{"issue":"19","key":"10104_CR115","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1136\/heartjnl-2024-324301","volume":"110","author":"J Wong","year":"2024","unstructured":"Wong, J., Soh, C. H., Wang, B., & Marwick, T. (2024). Long-term risk of heart failure in adult cancer survivors: A systematic review and meta-analysis. Heart, 110(19), 1188\u201395.","journal-title":"Heart"},{"issue":"24","key":"10104_CR116","doi-asserted-by":"publisher","first-page":"6161","DOI":"10.7150\/jca.36948","volume":"10","author":"G Li","year":"2019","unstructured":"Li, G., Zhou, Z., Yang, W., Yang, H., Fan, X., Yin, Y., et al. (2019). Long-term cardiac-specific mortality among 44,292 acute myeloid leukemia patients treated with chemotherapy: A population-based analysis. Journal of Cancer, 10(24), 6161\u20136169.","journal-title":"Journal of Cancer"},{"key":"10104_CR117","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3390\/cancers17152413","volume":"17","author":"L Torres-Mi\u00f1ana","year":"2025","unstructured":"Torres-Mi\u00f1ana, L., Boluda, B., Solana-Altabella, A., Rodr\u00edguez-Veiga, R., Cano, I., Acu\u00f1a-Cruz, E., et al. (2025). Cardiotoxicity in adult patients with relapsed or refractory acute myeloid leukemia. Cancers (Basel), 17, 15.","journal-title":"Cancers (Basel)"},{"issue":"12","key":"10104_CR118","first-page":"e51038","volume":"15","author":"R Sharma","year":"2023","unstructured":"Sharma, R., Kashyap, J., Olanrewaju, O. A., Jabbar, A., Someshwar, F., Saeed, H., et al. (2023). Cardio-oncology: Managing cardiovascular complications of cancer therapies. Cureus, 15(12), e51038.","journal-title":"Cureus"},{"key":"10104_CR119","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15082267","author":"B Boluda","year":"2023","unstructured":"Boluda, B., Solana-Altabella, A., Cano, I., Mart\u00ednez-Cuadr\u00f3n, D., Acu\u00f1a-Cruz, E., Torres-Mi\u00f1ana, L., et al. (2023). Incidence and risk factors for development of cardiac toxicity in adult patients with newly diagnosed acute myeloid leukemia. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers15082267","journal-title":"Cancers (Basel)"},{"key":"10104_CR120","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17152413","author":"L Torres-Mi\u00f1ana","year":"2025","unstructured":"Torres-Mi\u00f1ana, L., Boluda, B., Solana-Altabella, A., Rodr\u00edguez-Veiga, R., Cano, I., Acu\u00f1a-Cruz, E., et al. (2025). Cardiotoxicity in adult patients with relapsed or refractory acute myeloid leukemia. Cancers. https:\/\/doi.org\/10.3390\/cancers17152413","journal-title":"Cancers"},{"key":"10104_CR121","doi-asserted-by":"publisher","first-page":"4679","DOI":"10.1182\/blood-2019-124464","volume":"134","author":"R Gangaraju","year":"2019","unstructured":"Gangaraju, R., Bhatia, S., & Kenzik, K. (2019). Venous-thromboembolism in elderly patients with acute myeloid leukemia. Blood, 134, 4679.","journal-title":"Blood"},{"key":"10104_CR122","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13133714","author":"IG Scalia","year":"2024","unstructured":"Scalia, I. G., Gheyath, B., Tamarappoo, B. K., Moudgil, R., Otton, J., Pereyra, M., et al. (2024). Chemotherapy related cardiotoxicity evaluation-a contemporary review with a focus on cardiac imaging. Journal of Clinical Medicine. https:\/\/doi.org\/10.3390\/jcm13133714","journal-title":"Journal of Clinical Medicine"},{"key":"10104_CR123","doi-asserted-by":"publisher","first-page":"795602","DOI":"10.1155\/2015\/795602","volume":"2015","author":"P Angsutararux","year":"2015","unstructured":"Angsutararux, P., Luanpitpong, S., & Issaragrisil, S. (2015). Chemotherapy-Induced cardiotoxicity: Overview of the roles of oxidative stress. Oxidative Medicine and Cellular Longevity, 2015, 795602.","journal-title":"Oxidative Medicine and Cellular Longevity"},{"issue":"2","key":"10104_CR124","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1080\/17474086.2017.1270754","volume":"10","author":"S Giammarco","year":"2017","unstructured":"Giammarco, S., Chiusolo, P., Piccirillo, N., Di Giovanni, A., Metafuni, E., Laurenti, L., et al. (2017). Hyperleukocytosis and leukostasis: Management of a medical emergency. Expert Review of Hematology, 10(2), 147\u2013154.","journal-title":"Expert Review of Hematology"},{"issue":"11","key":"10104_CR125","first-page":"1549","volume":"90","author":"Y Nadir","year":"2005","unstructured":"Nadir, Y., Katz, T., Sarig, G., Hoffman, R., Oliven, A., Rowe, J. M., et al. (2005). Hemostatic balance on the surface of leukemic cells: The role of tissue factor and urokinase plasminogen activator receptor. Haematologica, 90(11), 1549\u20131556.","journal-title":"Haematologica"},{"key":"10104_CR126","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16233974","author":"NS Naji","year":"2024","unstructured":"Naji, N. S., Sathish, M., & Karantanos, T. (2024). Inflammation and related signaling pathways in acute myeloid leukemia. Cancers. https:\/\/doi.org\/10.3390\/cancers16233974","journal-title":"Cancers"},{"key":"10104_CR127","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.ejca.2023.02.019","volume":"185","author":"WCM Dempke","year":"2023","unstructured":"Dempke, W. C. M., Zielinski, R., Winkler, C., Silberman, S., Reuther, S., & Priebe, W. (2023). Anthracycline-induced cardiotoxicity \u2014 are we about to clear this hurdle? European Journal of Cancer, 185, 94\u2013104.","journal-title":"European Journal of Cancer"},{"key":"10104_CR128","doi-asserted-by":"publisher","DOI":"10.3390\/jox15010009","author":"Y Ma","year":"2025","unstructured":"Ma, Y., Grootaert, M. O. J., & Sewduth, R. N. (2025). Cardiotoxicity of chemotherapy: A multi-OMIC perspective. Journal of Xenobiotics. https:\/\/doi.org\/10.3390\/jox15010009","journal-title":"Journal of Xenobiotics"},{"key":"10104_CR129","doi-asserted-by":"crossref","unstructured":"Mitchell, J. D. P. M., Boehmer, J., Gorcsan, J., Eguchi, S., Orihara, Y., Dronamraju, N., Dhani, S., Faderl, S., Lin, T. L., & Uy, G. L. (2025). CPX-351 vs. conventional chemotherapy cardiotoxicity in high-risk AML: A post hoc phase III trial analysis. Cardio-Oncology.","DOI":"10.1186\/s40959-025-00421-7"},{"key":"10104_CR130","doi-asserted-by":"publisher","first-page":"3878","DOI":"10.1182\/blood-2015-01-623447","volume":"125","author":"AKRN Burnett","year":"2015","unstructured":"Burnett, A. K. R. N., Hills, R. K., Kell, J., Cavenagh, J., Kjeldsen, L., McMullin, M. F., Cahalin, P., Dennis, M., Friis, L., & Thomas, I. F. (2015). A randomized comparison of daunorubicin 90 mg\/m2 vs 60 mg\/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients. Blood, 125, 3878.","journal-title":"Blood"},{"key":"10104_CR131","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.lrr.2017.04.001","volume":"7","author":"PSS Vachhani","year":"2017","unstructured":"Vachhani, P. S. S., Baron, J., Thompson, J. E., Wetzler, M., Griffiths, E. A., Ontiveros, E. P., Spangenthal, E. J., & Wang, E. S. (2017). Dexrazoxane for cardioprotection in older adults with acute myeloid leukemia. Leukemia Research Reports, 7, 36.","journal-title":"Leukemia Research Reports"},{"key":"10104_CR132","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1016\/j.jacc.2014.06.1167","volume":"64","author":"PYE Vejpongsa","year":"2014","unstructured":"Vejpongsa, P. Y. E. (2014). Prevention of anthracycline-induced cardiotoxicity: Challenges and opportunities. Journal of the American College of Cardiology, 64, 938.","journal-title":"Journal of the American College of Cardiology"},{"key":"10104_CR133","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1007\/s10741-023-10328-z","volume":"28","author":"YWR Gao","year":"2023","unstructured":"Gao, Y. W. R., Jiang, J., Hu, Y., Li, H., & Wang, Y. (2023). ACEI\/ARB and beta-blocker therapies for preventing cardiotoxicity of antineoplastic agents in breast cancer: A systematic review and meta-analysis. Heart Failure Reviews, 28, 1405.","journal-title":"Heart Failure Reviews"},{"key":"10104_CR134","doi-asserted-by":"publisher","first-page":"e41","DOI":"10.1161\/CIR.0000000000000986","volume":"144","author":"MGBT Fradley","year":"2021","unstructured":"Fradley, M. G. B. T., Brown, S. A., Cheng, R. K., Dent, S. F., Nohria, A., Patton, K. K., Singh, J. P., & Olshansky, B. (2021). Recognition, prevention, and management of arrhythmias and autonomic disorders in cardio-oncology: A scientific statement from the American Heart Association. Circulation, 144, e41.","journal-title":"Circulation"},{"key":"10104_CR135","doi-asserted-by":"publisher","DOI":"10.1093\/ehjci\/jeac106","volume":"23","author":"ARLFT Lyon","year":"2022","unstructured":"Lyon, A. R. L. F. T., Couch, L. S., Asteggiano, R., Aznar, M. C., Bergler-Klein, J., Boriani, G., Cardinale, D., Cordoba, R., Cosyns, B., & Cutter, D. J. (2022). ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS) Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC). European Heart Journal-Cardiovascular Imaging, 23, Article e333.","journal-title":"European Heart Journal-Cardiovascular Imaging"},{"issue":"22","key":"10104_CR136","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1016\/j.jacc.2013.07.049","volume":"62","author":"AA Hussein","year":"2013","unstructured":"Hussein, A. A., Gottdiener, J. S., Bartz, T. M., Sotoodehnia, N., deFilippi, C., Dickfeld, T., et al. (2013). Cardiomyocyte injury assessed by a highly sensitive troponin assay and sudden cardiac death in The community: The cardiovascular health study. Journal of the American College of Cardiology, 62(22), 2112\u20132120.","journal-title":"Journal of the American College of Cardiology"},{"issue":"2","key":"10104_CR137","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1002\/ajh.26805","volume":"98","author":"I Graf","year":"2023","unstructured":"Graf, I., Greiner, G., Marculescu, R., Gleixner, K. V., Herndlhofer, S., Stefanzl, G., et al. (2023). N-terminal pro-brain natriuretic peptide is a prognostic marker for response to intensive chemotherapy, early death, and overall survival in acute myeloid leukemia. American Journal of Hematology, 98(2), 290\u2013299.","journal-title":"American Journal of Hematology"},{"issue":"4","key":"10104_CR138","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.currproblcancer.2018.05.005","volume":"42","author":"M Awadalla","year":"2018","unstructured":"Awadalla, M., Hassan, M. Z. O., Alvi, R. M., & Neilan, T. G. (2018). Advanced imaging modalities to detect cardiotoxicity. Current Problems in Cancer, 42(4), 386\u2013396.","journal-title":"Current Problems in Cancer"},{"key":"10104_CR139","doi-asserted-by":"publisher","first-page":"1275251","DOI":"10.3389\/fonc.2024.1275251","volume":"14","author":"K Bhatia","year":"2024","unstructured":"Bhatia, K., Sandhu, V., Wong, M. H., Iyer, P., & Bhatt, S. (2024). Therapeutic biomarkers in acute myeloid leukemia: Functional and genomic approaches. Frontiers in Oncology, 14, 1275251.","journal-title":"Frontiers in Oncology"},{"issue":"17","key":"10104_CR140","doi-asserted-by":"publisher","first-page":"5146","DOI":"10.1182\/bloodadvances.2022007699","volume":"6","author":"DR Anderson","year":"2022","unstructured":"Anderson, D. R., Stock, W., Karrison, T. G., & Leader, A. (2022). D-dimer and risk for thrombosis in adults with newly diagnosed acute lymphoblastic leukemia. Blood Advances, 6(17), 5146\u201351.","journal-title":"Blood Advances"},{"issue":"1","key":"10104_CR141","doi-asserted-by":"publisher","first-page":"1","DOI":"10.46701\/BG.20250100915","volume":"9","author":"Y Xie","year":"2025","unstructured":"Xie, Y., Kong, X., Zhang, H., Yan, C., Yin, Z., Li, H., et al. (2025). Platelet-derived microparticles and hematological diseases. Blood and Genomics, 9(1), 1\u201315.","journal-title":"Blood and Genomics"},{"key":"10104_CR142","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12113424","author":"M Li","year":"2020","unstructured":"Li, M., Lin, C., Leso, A., & Nefedova, Y. (2020). Quantification of citrullinated histone H3 bound DNA for detection of neutrophil extracellular traps. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers12113424","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10104_CR143","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-022-02359-5","volume":"41","author":"L Ronchetti","year":"2022","unstructured":"Ronchetti, L., Terrenato, I., Ferretti, M., Corrado, G., Goeman, F., Donzelli, S., et al. (2022). Circulating cell free DNA and citrullinated histone H3 as useful biomarkers of NETosis in endometrial cancer. Journal of Experimental & Clinical Cancer Research\u202f: J Exp Clin Cancer Res, 41(1), Article 151.","journal-title":"Journal of Experimental & Clinical Cancer Research : J Exp Clin Cancer Res"},{"key":"10104_CR144","doi-asserted-by":"publisher","first-page":"357","DOI":"10.2147\/CMAR.S47238","volume":"6","author":"SW Langer","year":"2014","unstructured":"Langer, S. W. (2014). Dexrazoxane for the treatment of chemotherapy-related side effects. Cancer Management and Research, 6, 357\u201363.","journal-title":"Cancer Management and Research"},{"key":"10104_CR145","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.jconrel.2021.08.023","volume":"338","author":"M Donnette","year":"2021","unstructured":"Donnette, M., Hamimed, M., Ciccolini, J., Berda-Haddad, Y., Kaspi, E., Venton, G., et al. (2021). Pharmacokinetics and pharmacogenetics of liposomal cytarabine in AML patients treated with CPX-351. Journal of Controlled Release, 338, 244\u201352.","journal-title":"Journal of Controlled Release"},{"issue":"3","key":"10104_CR146","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1177\/1753944716642677","volume":"10","author":"CM Ferrario","year":"2016","unstructured":"Ferrario, C. M. (2016). Cardiac remodelling and RAS inhibition. Therapeutic Advances in Cardiovascular Disease, 10(3), 162\u201371.","journal-title":"Therapeutic Advances in Cardiovascular Disease"},{"key":"10104_CR147","doi-asserted-by":"publisher","first-page":"749291","DOI":"10.3389\/fimmu.2021.749291","volume":"12","author":"HM Al-kuraishy","year":"2021","unstructured":"Al-kuraishy, H. M., Al-Gareeb, A. I., Mostafa-Hedeab, G., Kasozi, K. I., Zirintunda, G., & Aslam, A. (2021). Effects of \u03b2-blockers on the sympathetic and cytokines storms in Covid-19. Frontiers in Immunology, 12, 749291.","journal-title":"Frontiers in Immunology"},{"issue":"23_suppl_1","key":"10104_CR148","doi-asserted-by":"publisher","first-page":"III-39","DOI":"10.1161\/01.CIR.0000131517.20177.5a","volume":"109","author":"J Davignon","year":"2004","unstructured":"Davignon, J. (2004). Beneficial cardiovascular pleiotropic effects of statins. Circulation, 109(23_suppl_1), III-39\u2013III\u221243.","journal-title":"Circulation"},{"issue":"22","key":"10104_CR149","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1001\/jama.2023.7843","volume":"329","author":"D Schrag","year":"2023","unstructured":"Schrag, D., Uno, H., Rosovsky, R., Rutherford, C., Sanfilippo, K., Villano, J. L., et al. (2023). Direct oral anticoagulants vs Low-Molecular-Weight heparin and recurrent VTE in patients with cancer: A randomized clinical trial. Jama, 329(22), 1924\u20131933.","journal-title":"Jama"},{"issue":"1","key":"10104_CR150","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-50037-1","volume":"15","author":"W Kang","year":"2024","unstructured":"Kang, W., Huang, C., Yan, V. K. C., Wei, Y., Shami, J. J. P., Li, S. T. H., et al. (2024). Effectiveness and safety of continuous low-molecular-weight heparin versus switching to direct oral anticoagulants in cancer-associated venous thrombosis. Nature Communications, 15(1), Article 5657.","journal-title":"Nature Communications"},{"issue":"1","key":"10104_CR151","doi-asserted-by":"publisher","DOI":"10.1186\/s12959-025-00718-8","volume":"23","author":"S Cui","year":"2025","unstructured":"Cui, S., Jiang, R., Zhao, J., Wang, J., Hu, B., Li, H., et al. (2025). Thromboelastography-based dynamic evaluation of perioperative coagulation changes and anticoagulant efficacy in lung cancer patients. Thrombosis Journal, 23(1), Article 31.","journal-title":"Thrombosis Journal"},{"issue":"1","key":"10104_CR152","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.124.038782","volume":"14","author":"JR Shaw","year":"2025","unstructured":"Shaw, J. R., Nopp, S., Stavik, B., Youkhana, K., Michels, A. L., Kennes, S., et al. (2025). Thrombosis, translational medicine, and biomarker research: Moving the needle. Journal of the American Heart Association, 14(1), Article e038782.","journal-title":"Journal of the American Heart Association"},{"issue":"23","key":"10104_CR153","doi-asserted-by":"publisher","first-page":"e019628","DOI":"10.1161\/JAHA.120.019628","volume":"9","author":"YHY Zhou","year":"2020","unstructured":"Zhou, Y. H. Y., Hussain, M., Brown, S. A., Budd, T., Tang, W. W., Abraham, J., Xu, B., Shah, C., Moudgil, R., & Popovic, Z. (2020). Machine learning\u2013based risk assessment for cancer therapy\u2013related cardiac dysfunction in 4300 longitudinal oncology patients. Journal of the American Heart Association, 9(23), e019628.","journal-title":"Journal of the American Heart Association"},{"key":"10104_CR154","doi-asserted-by":"publisher","first-page":"e14614","DOI":"10.1002\/acm2.14614","volume":"26","author":"ABRA Talebi","year":"2025","unstructured":"Talebi, A. B. R. A., Alizadeh-asl, A., Seilani, P., Khajetash, B., Hajianfar, G., & Tavakoli, M. (2025). Machine learning based radiomics model to predict radiotherapy induced cardiotoxicity in breast cancer. Journal of Applied Clinical Medical Physics, 26, e14614.","journal-title":"Journal of Applied Clinical Medical Physics"},{"key":"10104_CR155","doi-asserted-by":"publisher","DOI":"10.2196\/63964","volume":"11","author":"H Mushcab","year":"2025","unstructured":"Mushcab, H., Al Ramis, M., AlRujaib, A., Eskandarani, R., Sunbul, T., AlOtaibi, A., Obaidan, M., Al Harbi, R., & Aljabri, D. (2025). Application of artificial intelligence in cardio-oncology imaging for cancer therapy-related cardiovascular toxicity: Systematic review. JMIR Cancer, 11, Article e63964.","journal-title":"JMIR Cancer"},{"key":"10104_CR156","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.jtha.2024.11.001","volume":"23","author":"KZY Chen","year":"2025","unstructured":"Chen, K. Z. Y., Zhang, L., Zhang, W., & Chen, Y. (2025). Machine learning models for risk prediction of cancer-associated thrombosis: a systematic review and meta-analysis. Journal of Thrombosis and Haemostasis, 23, 610.","journal-title":"Journal of Thrombosis and Haemostasis"}],"container-title":["Cardiovascular Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12012-026-10104-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12012-026-10104-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12012-026-10104-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T19:02:15Z","timestamp":1774119735000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12012-026-10104-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,24]]},"references-count":156,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10104"],"URL":"https:\/\/doi.org\/10.1007\/s12012-026-10104-z","relation":{},"ISSN":["1530-7905","1559-0259"],"issn-type":[{"value":"1530-7905","type":"print"},{"value":"1559-0259","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,24]]},"assertion":[{"value":"28 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"31"}}